Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients
Open Access
- 27 December 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (6) , 784-800
Abstract
Despite multimodal treatment, the prognosis of high-grade gliomas is grim. As tumor growth is critically dependent on new blood vessel formation, antiangiogenic treatment approaches offer an innovative treatment strategy. Bevacizumab, a humanized monoclonal antibody, has been in the spotlight of antiangiogenic approaches for several years. Currently, MRI including contrast-enhanced T1-weighted and T2/fluid-attenuated inversion recovery (FLAIR) images is routinely used to evaluate antiangiogenic treatment response (Response Assessment in Neuro-Oncology criteria). However, by restoring the blood–brain barrier, bevacizumab may reduce T1 contrast enhancement and T2/FLAIR hyperintensity, thereby obscuring the imaging-based detection of progression. The aim of this review is to highlight the recent role of imaging biomarkers from MR and PET imaging on measurement of disease progression and treatment effectiveness in antiangiogenic therapies. Based on the reviewed studies, multimodal imaging combining standard MRI with new physiological MRI techniques and metabolic PET imaging, in particular amino acid tracers, may have the ability to detect antiangiogenic drug susceptibility or resistance prior to morphological changes. As advances occur in the development of therapies that target specific biochemical or molecular pathways and alter tumor physiology in potentially predictable ways, the validation of physiological and metabolic imaging biomarkers will become increasingly important in the near future.Keywords
This publication has 99 references indexed in Scilit:
- Sustained focal antitumor activity of bevacizumab in recurrent glioblastomaNeurology, 2014
- Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: A longitudinal MRI studyEuropean Journal of Radiology, 2014
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab TherapyClinical Cancer Research, 2014
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastomaNeurology, 2014
- An Intra-Individual Comparison of MRI, [18F]-FET and [18F]-FLT PET in Patients with High-Grade GliomasPLOS ONE, 2014
- Comparison of 18F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain TumorsJournal of Nuclear Medicine, 2014
- Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade gliomaNeuro-Oncology, 2014
- Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent GlioblastomaAmerican Journal of Neuroradiology, 2013
- Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma MultiformeAmerican Journal of Neuroradiology, 2013
- Time course of imaging changes of GBM during extended bevacizumab treatmentJournal of Neuro-Oncology, 2008